| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3283299 | Clinical Gastroenterology and Hepatology | 2012 | 6 Pages |
Abstract
NASH is associated with significantly higher levels of non-HDL-C than steatosis in patients who do not take lipid-lowering agents. This low-cost biomarker could be used in noninvasive differentiation between steatosis and NASH.
Keywords
NASVLDLNon–HDL-CIDLNAFLD3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitorsBlood testnonalcoholic steatohepatitisNonalcoholic fatty liver diseaseDiagnosticvery low density lipoproteinIntermediate density lipoproteinNonalcoholic fatty liver disease activity scoreNash Clinical trialtotal cholesterol
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
Kathleen E. Corey, Michelle Lai, Louis G. Gelrud, Joseph Misdraji, Lydia L. Barlow, Hui Zheng, Karin L. Andersson, Michael Thiim, Daniel S. Pratt, Raymond T. Chung,